Gene Therapy Death Raises Ethical Issues
By Marcy Darnovsky,
San Francisco Chronicle
| 09. 13. 2007
Later this month, a committee of the National Institutes of Health will discuss the recent death of 36-year-old Illinois resident Jolee Mohr in an experimental gene therapy study sponsored by Targeted Genetics Corporation. The NIH committee is an advisory body only, but its meeting may provide Mohr's family - and the rest of us - a rare glimpse into the inner workings of the clinical trial enterprise in the United States.
Real regulatory and oversight authority for gene therapy and other clinical trials rests with the Food and Drug Administration. The FDA conducts much of its work behind closed doors in order to protect the proprietary interests of the studies' sponsors. The unfortunate result is a deficit of transparency and accountability, and an unknowable amount of dirty linen hidden away.
The FDA is investigating Mohr's death, and hasn't yet announced whether it will be attributed to the gene transfer. But Mohr died following a fever of 105 degrees and multiple organ failure, symptoms that began to develop just after she was injected with the genes carried by engineered viruses.
Gene...
Related Articles
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...